Insomnia and inflammatory exposure impair spatial memory and cognitive mapping in older adults: a randomized controlled trial.

Brain Behav ImmunJun 8, 2026 (epub)
Clinical ResearchGeriatricsPsychiatry

Dominique Piber, Richard Olmstead, Joshua Hyong-Jin Cho et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial investigated the impact of insomnia and inflammatory exposure on spatial memory and cognitive mapping in 84 older adults aged 60-80. Results indicated that those with insomnia exhibited significant impairments in both cognitive functions compared to controls, particularly after endotoxin exposure, highlighting the interaction between insomnia and inflammation in cognitive aging.

Key findings

  • Older adults with insomnia showed significant impairments in spatial memory and cognitive mapping compared to controls (P's < 0.01).
  • A significant interaction was found between insomnia and endotoxin exposure affecting cognitive mapping (P < 0.05).
  • Deficits in cognitive mapping were observed in insomnia patients exposed to endotoxin (P < 0.01).

Why it matters

Understanding the interplay between insomnia and inflammation is crucial for addressing cognitive decline in older adults. Identifying these factors may help in developing targeted interventions to preserve cognitive function during aging.

Source

PubMed · PMID 42264275

Published in Brain Behav Immun. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.